Analysis of permanent brachytherapy combined with maximal androgen blockade in local intermediated-risk prostate cancer / 中华外科杂志
Chinese Journal of Surgery
;
(12): 257-260, 2015.
Artículo
en Chino
| WPRIM
| ID: wpr-308561
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the outcomes of permanent brachytherapy combined with maximal androgen blockade (MAB) in local intermediated-risk prostate cancer.</p><p><b>METHODS</b>From December 2003 to December 2009, 307 patients of local prostate cancer were treated with brachytherapy, 98 cases of intermediated-risk were followed-up for 5 years and data were recorded, aged from 58 to 84 years, average 74 years. Serum PSA was 0.4-19.0 µg/L, average 11.2 µg/L, clinical TNM stage was T1cN0M0-T2bN0M0. Gleason score 4-7, 6.7 in average. Prostate volume ranged from 14 to 65 ml, average 32.1 ml. All the 98 patients underwent permanent brachytherapy combined with MAB. Biochemical recurrence rate, biochemical-free survival, tumor-specific survival, overall survival, salvage therapy and complications were analyzed.</p><p><b>RESULTS</b>Followed up for 5 years, 19 cases had biochemical recurrence, median recurrence period 36 months. One patient died of prostate cancer 45 months after brachytherapy of all 7 patients died in 5 years. Five-years biochemical-free recurrence rate 80.6%, overall survival 92.9%, tumor-specific survival 98.9%, biochemical-free survival 79.3%. Low-urinary tract and rectal irritation symptoms occurred in 75 cases(76.5%). Urinary retention occurred in 7 cases (7.1%) with catheterization duration less than 1 week, no surgical operation were performed. Seeds immigration to lung in 2 cases. No serious complications occurred.</p><p><b>CONCLUSION</b>In local intermediated-risk prostate cancer patients, permanent brachytherapy combined with short-term MAB can be an effective treatment with few complications.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias de la Próstata
/
Radioterapia
/
Sangre
/
Braquiterapia
/
Resultado del Tratamiento
/
Antígeno Prostático Específico
/
Terapia Combinada
/
Usos Terapéuticos
/
Quimioterapia
/
Antagonistas de Andrógenos
Tipo de estudio:
Estudio de etiología
Límite:
Anciano
/
Aged80
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Chinese Journal of Surgery
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS